Further, we found that besides CA, other structurally distinct Nrf2 activators, including the multiple sclerosis drugs dimethyl fumarate (DMF) and monomethyl fumarate (MMF) [27], synergistically potentiated the antileukemic effects of several VDDs on different AML cell types [28]. The gene discussed is NFE2L2; the disease is multiple sclerosis.